The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to ...

Talphera Inc (TLPH) secures significant investment and FDA approvals, while navigating challenges in clinical trials and ...

The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the ...

Though the CRRT solutions may require patient-specific adjustments, the work group determined that a standardized system for prescribing, processing, compounding, and verifying CRRT solutions was ...

All patients undergoing CRRT while on ECLS between 2005 and 2010 at Seattle Children's Hospital (n = 42) were identified by a retrospective review of a prospectively maintained institutional database.

Talphera (TLPH) announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously ...

(RTTNews) - Specialty pharmaceutical company Talphera, Inc. (TLPH), Monday announced its agreement with the FDA to reduce the size of the NEPHRO CRRT study to 70 patients from the 166 previously ...

The recent announcements of the FDA’s approval to reduce the study size to 70 patients, the private placement financing, and FDA-agreed study ...

To provide medical professionals (RN, MD, Pharmacist) with the knowledge and understanding for decision making for the effective utilization of Continuous Renal Replacement Therapy (CRRT) and to allow ...